Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer
Journal of Controlled Release · 2024-08 · 372 · 176-193
DOI: 10.1016/j.jconrel.2024.06.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-08. Verfasst von Ha Rin Kim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.; School of Medicine, S…. Hauptthemen laut MEDLINE: Pinocytosis, Proto-Oncogene Proteins p21(ras), Peptides, Protein Kinase Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
KRAS-mutant cancers, due to their protein targeting complexity, present significant therapeutic hurdles. The identification of the macropinocytic phenotype in these cancers has emerged as a promising alternative therapeutic target. Our study introduces MPD1, an macropinocytosis-targeting peptide-drug conjugates (PDC), which is developed to treat KRAS mutant cancers. This PDC is specifically designed to trigger a positive feedback loop through its caspase-3 cleavable characteristic. However, we observe that this loop is hindered by DNA-PK mediated DNA damage repair processes in cancer cells. To counter this impediment, we employ AZD7648, a DNA-PK inhibitor. Interestingly, the combined treatment of MPD1 and AZD7648 resulted in a 100% complete response rate in KRAS-mutant xenograft model. We focus on the synergic mechanism of it. We discover that AZD7648 specifically enhances macropinocytosis in KRAS-mutant cancer cells. Further analysis uncovers a significant correlation between the increase in macropinocytosis and PI3K signaling, driven by AMPK pathways. Also, AZD7648 reinforces the positive feedback loop, leading to escalated apoptosis and enhanced payload accumulation within tumors. AZD7648 possesses broad applications in augmenting nano-sized drug delivery and preventing DNA repair resistance. The promising efficacy and evident synergy underscore the potential of combining MPD1 with AZD7648 as a strategy for treating KRAS-mutant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.; School of Medicine, Stanford University, CA 94305, United States.
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
- College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, United States.
- Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, United States.
- College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea.
- Chemical & Biological Integrative Research Center, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea.
Zitieren
APA
Kim, H. R., Park, S. J., Cho, Y. S., Moyo, M. K., Choi, J. U., Lee, N. K., Chung, S. W., Kweon, S., Park, J., Kim, B., Ko, Y. G., Yeo, J. H., Lee, J., Kim, S. Y., & Byun, Y. (2024). Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer. Journal of Controlled Release, 372, 176-193. https://doi.org/10.1016/j.jconrel.2024.06.028
Vancouver
Kim HR, Park SJ, Cho YS, Moyo MK, Choi JU, Lee NK, et al. Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer. Journal of Controlled Release. 2024;372:176-193. doi:10.1016/j.jconrel.2024.06.028
BibTeX
@article{Kim2024,
author = {Kim, Ha Rin and Park, Seong Jin and Cho, Young Seok and Moyo, Mudhibadhi Knowledge and Choi, Jeong Uk and Lee, Na Kyeong and Chung, Seung Woo and Kweon, Seho and Park, Jooho and Kim, Byoungmo and Ko, Yoon Gun and Yeo, Joo Hye and Lee, Jinu and Kim, Sang Yoon and Byun, Youngro},
title = {Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer},
journal = {Journal of Controlled Release},
year = {2024},
volume = {372},
pages = {176--193},
doi = {10.1016/j.jconrel.2024.06.028}
}
EUVIMED